Han, Zheng
Wu, Xiaohui
Roelle, Sarah
Chen, Chuheng
Schiemann, William P.
Lu, Zheng-Rong
Article History
Received: 5 January 2017
Accepted: 25 July 2017
First Online: 25 September 2017
Change Date: 8 January 2018
Change Type: Correction
Change Details: In the original version of this Article, the penultimate sentence of the Abstract incorrectly read ‘The dose of the contrast agent for effective molecular MRI is only slightly lower than that of ZD2-Cy5.5 (0.5 µmol kg−1) in fluorescence imaging.’ The correct version states ‘higher’ in place of ‘lower’. This error has been corrected in both the PDF and HTML versions of the Article.
Competing interests
: The peptide and related targeted MRI contrast agents and imaging probes are licensed to Molecular Theranostics LLC. for clinical development. Z.H. and Z.-R.L. are the inventors of the patent and on the patent application. Z.-R.L. is one of co-founders of Molecular Theranostics LLC and has ownership interest of the company.